BostonGene Advances AI-Driven Disease Modeling in Oncology in Collaboration with Leading Experts in Cancer Genomics at USCAP 115th Annual Meeting

New data, presented by leading oncology experts, demonstrate a multimodal AI framework for resolving complex cancers and guiding treatment decisions

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced an oral presentation at the United States and Canadian Academy of Pathology (USCAP) 115th Annual Meeting. The session highlights new clinical data generated in collaboration with leading academic investigators, including Weill Cornell Medicine.

The event, held from March 21-26 at the Henry B. González Convention Center in San Antonio, TX, is the world's premier gathering for pathology professionals serving as a critical global platform for clinicians and researchers to exchange cutting-edge research and educational insights across pathology subspecialties, with a particular focus on the integration of AI and molecular advancements into clinical practice.

The study, which demonstrates a multimodal AI framework trained on approximately 20,000 tumors, will be presented by Juan Miguel Mosquera, MD, MSc. Dr Mosquera is a Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine and Director of Research Pathology at the Englander Institute for Precision Medicine, and is widely recognized for his contributions to cancer genomics and biomarker development with more than 130 peer-reviewed publications.

The research integrated whole exome and transcriptomic data to address cancers of unknown primary (CUP). In real-world cases, the framework accurately identified tumor origin while uncovering actionable therapeutic targets in more than 65% of patients, including FDA-approved options.

The results reflect a broader shift from traditional tumor classification toward AI-driven disease modeling, enabling deeper biological understanding, more precise patient stratification, and improved treatment selection.

Details of the oral presentation are below:

Abstract: 942
Title: Cancer of Unknown Primary (CUP): Beyond the Identification of the Tumor of Origin by an Integrative Whole Exome (WES) and Transcriptome Sequencing (RNAseq) Approach
Date & Time: Tuesday, March 24 | 8:30 AM - 8:45 AM
Location: Room 303B
Presenter: Juan Miguel Mosquera, MD, MSc, Weill Cornell Medicine

Research done in collaboration with Weill Cornell Medicine

For more information please contact Hannah Oman at [e-mail].

About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.